Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

Ritlecitinib is safe and may effectively treat alopecia areata.

A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Gefitinib therapy can cause unusual hair growth on the nose.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.

Afatinib often causes skin problems that need proactive management.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.